Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming

Piperlongumine elevates reactive oxygen species levels, exploiting the heightened oxidative stress susceptibility of senescent cells.

“Piperlongumine elevates reactive oxygen species (ROS) levels, exploiting the heightened oxidative stress susceptibility of SnCs47.”

• cites [47] Wang, Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging 8, 2915–2926 (2016). sourceDisputed

  The Results section reports that piperlongumine elevated ROS in senescent WI-38 cells, supporting the first part of the claim. But the same section concludes that ROS were not involved in piperlongumine-induced senescent-cell death: an antioxidant reversed the ROS increase without preventing cell death. This contradicts the claim that piperlongumine exploits oxidative-stress susceptibility to kill those cells. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Preclinical studies have shown that senescent cell clearance can impair liver regeneration and wound healing under certain conditions.

“Preclinical studies have shown that SnC clearance can impair liver regeneration and wound healing under certain conditions, emphasizing the need to differentiate transient, beneficial senescence from chronic, pathological accumulation133–135.”

• cites [133] Ocampo, A. et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 167, 1719–1733.e1712 (2016). sourceCould not verify

  The section on partial reprogramming and cellular aging reports reduced senescence-associated activity after OSKM induction, not clearance of senescent cells. Searches for senescent-cell clearance, liver regeneration, and wound healing found no passage in our copy addressing whether clearance impairs either process. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [134] Krizhanovsky, V. et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134, 657–667 (2008). sourceDisputed

  The Discussion (page unavailable) says immune clearance of senescent hepatic stellate cells facilitates resolution of liver fibrosis; inhibiting that clearance delays resolution. This is contrary to the attributed finding that clearance impairs healing. The paper does not report impaired liver regeneration from senescent-cell clearance. (LLM, conf=0.84)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [135] Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722–733 (2014). sourcePartly supported

  The Results section, “Elimination of Senescent Cells Delays Cutaneous Wound Healing” (page unavailable), reports that eliminating senescent cells delayed wound closure in mice. The paper mentions senescent cells in liver injury and repair, but our copy does not report that their clearance impairs liver regeneration. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

The progressive accumulation of senescent cells promotes chronic inflammation through the senescence-associated secretory phenotype (SASP).

“The progressive accumulation of senescent cells (SnCs) promotes chronic inflammation through the senescence-associated secretory phenotype (SASP)”

• Also stated in: § Evolution of senescent cell (SnC) research · plain

  “secrete a pro-inflammatory mixture of cytokines, chemokines, and proteases collectively termed the senescence-associated secretory phenotype (SASP)10,11”

• cites [10] Wang, B. et al. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol. 25, 958–978 (2024). sourceCould not verify

  The passages from our copy contain bibliographic information, not a discussion of senescent-cell accumulation or inflammation. Searches for “chronic inflammation,” “accumulation of senescent cells,” and SASP-related inflammatory secretions found no passage addressing the claim. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [11] Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 18, e3000599 (2020). sourceSupported

PET imaging probes targeting SA-β-Gal, such as [68Ga]Ga-BGal, have demonstrated efficacy in preclinical models.

“For example, probes targeting SA-β-Gal, such as [68Ga]Ga-BGal, have demonstrated efficacy in preclinical models112,113.”

• cites [112] Xiang, X. et al. Novel PET imaging probe for quantitative detection of senescence in vivo. J. Med. Chem. 67, 5924–5934 (2024). sourceSupported
• cites [113] Alum, E. U. et al. Targeting cellular senescence for healthy aging: advances in senolytics and senomorphics. Drug Des. Dev. Ther. 19, 8489–8522 (2025). sourcePartly supported

  The Clinical Validation of Senescence Biomarkers section (page unavailable) says SA-β-galactosidase shows promise as a marker in experimental models and discusses molecular imaging as a potential monitoring approach. It does not identify [68Ga]Ga-BGal or report that an SA-β-Gal-targeted PET probe demonstrated efficacy in preclinical models. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Inhibiting SCAPs disrupts the survival machinery of senescent cells, triggering their selective apoptosis while sparing normal cells in some contexts.

“Inhibiting these SCAPs disrupts the survival machinery of SnCs, triggering their selective apoptosis while sparing normal cells in some contexts26,27”

• cites [26] Wang, Y. et al. Implication of cellular senescence in the progression of chronic kidney disease and the treatment potencies. Biomed. Pharmacother. 135, 111191 (2021). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [27] Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 28, 1556–1568 (2022). sourceSupported

In a pilot study in diabetic kidney disease (NCT02848131), a 3-day course of D+Q reduced senescent cell burden in adipose tissue.

“In a pilot study in diabetic kidney disease (NCT02848131), a 3-day course reduced SnC burden in adipose tissue20.”

• cites [20] Hickson, L. J. et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446–456 (2019). sourceSupported

Targeting GD3 ganglioside carries a risk of autoimmunity, particularly in older individuals with pre-existing immune dysregulation.

“targeting this pathway carries a risk of autoimmunity, particularly in older individuals with pre-existing immune dysregulation59,60.”

• cites [59] Khandwala, P., Desai, D. & Lau, A. Prevalence of autoimmune diseases in patients treated with immune checkpoint inhibitors: an epidemiological study using a global network of health care organizations. ACR Open Rheumatol. 7, e11787 (2025). sourcePartly supported

  The Introduction says that blocking immune checkpoints may break self-tolerance and cause immune-related adverse effects, and the Discussion reports increased autoimmune-condition risk among patients receiving checkpoint inhibitors. The paper does not address GD3 ganglioside targeting or show that the risk is particularly high in older individuals with pre-existing immune dysregulation. No page numbers are available in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [60] Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019). sourceCould not verify

  The LAG-3 and TIM-3 sections discuss immune-checkpoint signaling and cancer treatment, but do not address targeting GD3 ganglioside or an associated risk of autoimmunity in older people. Searches for GD3, autoimmune toxicity, and pre-existing immune dysregulation found no passage supporting the attributed claim. (LLM, conf=0.74)

  Experimental — accuracy not yet measured

Bafilomycin A1 disrupts cytoprotective autophagy in senescent cells, leading to accumulation of damaged mitochondria and apoptotic cell death.

“bafilomycin A1 disrupts cytoprotective autophagy in SnCs, leading to accumulation of damaged mitochondria and apoptotic cell death51.”

• cites [51] L’Hôte, V. et al. Ouabain and chloroquine trigger senolysis of BRAF-V600E-induced senescent cells by targeting autophagy. Aging Cell 20, e13447 (2021). sourcePartly supported

  The Results section (‘Autophagy inhibitors are senolytic in BRAF senescence’; page unavailable) reports that bafilomycin A1 was senolytic in BRAF-V600E-induced senescent fibroblasts, though less potent than chloroquine. The Discussion reports bafilomycin A1-induced apoptosis in therapy-induced senescent mouse lymphomas. Our copy does not report accumulation of damaged mitochondria, and these findings do not establish the stated mechanism across senescent cells generally. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

By recruiting E3 ligases with tissue-restricted expression, PROTACs can achieve organ- or tissue-specific protein degradation, minimizing systemic toxicity.

“Enhanced Specificity: By recruiting E3 ligases with tissue-restricted expression, PROTACs can achieve organ- or tissue-specific protein degradation, minimizing systemic toxicity84–86.”

• cites [84] Madhukar, G. et al. E3 ubiquitin ligases and their therapeutic potential in disease management. Biochem. Pharmacol. 236, 116875 (2025). sourceNot checked — no full text of the source
• cites [85] Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015). sourcePartly supported

  The Results sections on PROTAC-mediated degradation and efficient in vivo knockdown show E3-ligase recruitment and protein degradation in mouse tissues. They do not show recruitment of tissue-restricted E3 ligases or reduced systemic toxicity; the tested PROTAC reduced ERRα in heart, kidney, and tumors rather than demonstrating organ-specific degradation. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [86] Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67–77.e63 (2018). sourcePartly supported

  The Introduction explains that PROTACs recruit an E3 ligase to degrade a target protein and mentions reduced toxicity as a potential advantage over hydrophobic tagging. It does not say that recruiting tissue-restricted E3 ligases produces organ- or tissue-specific degradation or thereby minimizes systemic toxicity. No page numbers are available in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

A single PROTAC molecule can mediate the degradation of multiple target proteins, enabling higher potency at lower doses.

“Catalytic Activity: A single PROTAC molecule can mediate the degradation of multiple target proteins, enabling higher potency at lower doses;”

• cites [84] Madhukar, G. et al. E3 ubiquitin ligases and their therapeutic potential in disease management. Biochem. Pharmacol. 236, 116875 (2025). sourceNot checked — no full text of the source
• cites [85] Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015). sourceSupported
• cites [86] Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67–77.e63 (2018). sourcePartly supported

  The Results and Discussion describe PROTACs as catalytic and report greater potency for PROTAC 1 than a comparable inhibitor (IC50 102 nM versus 171 nM). The Significance section also says degraders generally inhibited signalling and proliferation at lower concentrations. The paper does not establish that a single PROTAC molecule’s repeated degradation of targets is what causes that potency advantage. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

The FOXO4-DRI peptide disrupts the FOXO4-p53 interaction, promoting selective apoptosis in senescent cells.

“The FOXO4-DRI peptide disrupts the FOXO4–p53 interaction, promoting selective apoptosis in SnCs44–46.”

• cites [44] Huang, Y., He, Y., Makarcyzk, M. J. & Lin, H. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Front. Bioeng. Biotechnol. 9, 677576 (2021). sourceSupported
• cites [45] Bourgeois, B. et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat. Commun. 16, 5672 (2025). sourceSupported
• cites [46] Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132–147.e116 (2017). sourceSupported

Omega-3 fatty acids, when administered alongside senolytic therapies, may modulate the transient inflammatory responses associated with senescent cell clearance.

“When administered alongside senolytic therapies, they may modulate the transient inflammatory responses associated with SnC clearance104.”

• cites [104] Shvedova, M. et al. Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing. Aging 17, 16–32 (2024). sourcePartly supported

  The Discussion describes transient inflammation following ABT-263 treatment and suggests it may result from senolysis-induced immune activation. The paper does not address omega-3 fatty acids or whether administering them alongside senolytics modulates that response (searched: omega-3 and co-treatment). (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Transient, targeted interventions may be safer and more effective than permanent, systemic elimination of senescent cells.

“This duality highlights that transient, targeted interventions may be safer and more effective than permanent, systemic elimination of SnCs136.”

• cites [136] Lavarti, R. et al. The context-dependent effect of cellular senescence: from embryogenesis and wound healing to aging. Ageing Res. Rev. 109, 102760 (2025). sourcePartly supported

  The wound-healing section (page unavailable) says transient senescence helps tissue repair, while the therapeutic section describes intermittent treatment and targeted approaches, including one with less platelet toxicity. These passages support the rationale for selective intervention, but the paper does not establish that transient, targeted interventions are generally safer and more effective than permanent, systemic elimination of senescent cells. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Partial epigenetic reprogramming leverages transient expression of Yamanaka factors to rejuvenate cells and reverse senescence markers without inducing cell death, offering a route toward cellular restoration rather than removal.

“An emerging, conceptually transformative frontier is partial epigenetic reprogramming, which leverages transient expression of Yamanaka factors to rejuvenate cells and reverse senescence markers without inducing cell death, offering a route toward cellular restoration rather than removal143–145.”

• cites [143] Yang, J. H. et al. Loss of epigenetic information as a cause of mammalian aging. Cell 186, 305–326.e327 (2023). sourcePartly supported

  The Results section, “Epigenetic reprogramming restores a youthful epigenome in ICE mice” (page not available), reports that OSK reversed age-associated gene-expression and DNA-methylation changes in ICE cells and rejuvenated aging markers in mouse tissues. It does not show that OSK reversed the senescence indicators described elsewhere in the Results, or establish that reprogramming occurred without cell death. The reported absence of an apoptosis change concerns the earlier induction of DNA breaks, not OSK treatment. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [144] Sarkar, T. J. et al. Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells. Nat. Commun. 11, 1545 (2020). sourcePartly supported

  The Results (page unavailable in our copy) report that transient expression of OSKMLN reverses several cellular aging hallmarks. They also report reduced senescence-associated staining and cytokines in aged endothelial cells, but not in fibroblasts. The paper describes restoration of cell function while preserving identity, but the passages found do not establish that treatment causes no cell death; its Methods describe a viability assay, not a result resolving that point. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [145] Lu, J. Y. et al. Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming. Cell 188, 5895–5911.e5817 (2025). sourceNot checked — no full text of the source

Machine learning pipelines have predicted synergistic drug combinations, substantially reducing the time and cost of discovery.

“Machine learning pipelines, trained on extensive chemical compound datasets, have already identified novel small-molecule senolytics, such as Ginkgetin, Periplocin, and Oleandrin, and predicted synergistic drug combinations, substantially reducing the time and cost of discovery127,128.”

• cites [127] Wong, F. et al. Discovering small-molecule senolytics with deep neural networks. Nat. Aging 3, 734–750 (2023). sourceNot checked — no full text of the source
• cites [128] Smer-Barreto, V. et al. Discovery of senolytics using machine learning. Nat. Commun. 14, 3445 (2023). sourcePartly supported

  The Discussion (page unavailable) reports that the machine-learning pipeline reduced experimental screening by more than 200-fold and significantly reduced screening costs. The Results describe predictions of individual senolytic compounds, not synergistic drug combinations, and the cited passages do not establish a reduction in discovery time. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Immune-based senotherapies inherently carry the risk of immune-related adverse events, including autoimmunity and cytokine release syndrome (CRS).

“Immune-based senotherapies inherently carry the risk of immune-related adverse events, including autoimmunity and CRS.”

• cites [118] Wang, X. et al. Rejuvenation strategy for inducing and enhancing autoimmune response to eliminate senescent cells. Aging Dis. 16, 2273–2292 (2024). sourcePartly supported

  The CAR-T cells section (page unavailable) identifies cytokine release syndrome (CRS) as a prevalent adverse reaction to CAR-T therapy. It does not identify autoimmunity as an adverse event or establish that immune-based senotherapies generally carry both risks; the CAR-NK cells section says CAR-NK cells do not elicit CRS. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [119] Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120, 63–68 (2019). sourcePartly supported

  The Introduction says cancer immune checkpoint inhibitors carry a risk of immune-related adverse events, including autoimmune toxicities; the Results also describe autoimmune toxicities in treated patients. The paper does not address immune-based senotherapies or identify cytokine release syndrome as an adverse event. Its findings therefore support only the general immunotherapy and autoimmunity portion of the claim. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Senescent cells circumvent immune-mediated clearance by upregulating pro-survival and immune checkpoint pathways.

“circumvents immune-mediated clearance by upregulating pro-survival and immune checkpoint pathways”

• Also stated in: § Evolution of senescent cell (SnC) research · plain

  “SnCs possess strong anti-apoptotic mechanisms, primarily driven by the upregulation of BCL-2 family proteins, enabling them to resist programmed cell death7,8”

• cites [7] Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016). sourceNot checked yet

  A check is scheduled.

• cites [8] Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging cell 14, 644–658 (2015). sourceNot checked yet

  A check is scheduled.

• cites [9] Iltis, C. et al. A ganglioside-based immune checkpoint enables senescent cells to evade immunosurveillance during aging. Nat. Aging 5, 219–236 (2025). sourceNot checked yet

  A check is scheduled.

Microbiota-derived metabolites including butyrate may indirectly influence the hepatic microenvironment, potentially enhancing the efficacy of senolytic interventions by attenuating chronic inflammation and creating a metabolic state less permissive to cellular senescence.

“Through the gut–liver axis, microbiota-derived metabolites including butyrate may indirectly influence the hepatic microenvironment, potentially enhancing the efficacy of senolytic interventions by attenuating chronic inflammation and creating a metabolic state less permissive to cellular senescence101.”

• cites [101] Saeedi Saravi, S. S. et al. Gut microbiota-dependent increase in phenylacetic acid induces endothelial cell senescence during aging. Nat. Aging 5, 1025–1045 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Current research has shifted toward precision senotherapy.

“Consequently, current research has shifted toward precision senotherapy, though significant translational challenges remain.”

Omega-3 fatty acids may facilitate timely resolution of the regenerative response, preventing maladaptive chronic inflammation and fostering a microenvironment more favorable for tissue repair.

“Rather than suppressing the regenerative potential of this response, Omega-3 fatty acids may facilitate its timely resolution, preventing maladaptive chronic inflammation and thereby fostering a microenvironment more favorable for tissue repair.”

Radioligands targeting fibroblast activation protein (FAP) are emerging as tools for visualizing senescence-driven fibrosis.

“Additionally, radioligands targeting fibroblast activation protein (FAP) are emerging as tools for visualizing senescence-driven fibrosis114.”

• cites [114] Lindner, T. et al. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm. Chem. 4, 16 (2019). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics exhibit dose-dependent thrombocytopenia.

“these agents exhibited notable drawbacks, such as dose-dependent thrombocytopenia, variable therapeutic efficacy, and the emergence of resistance mechanisms.”

• Also stated in: § Representative agents in greater detail · plain

  “clinical applicability is limited by dose-dependent thrombocytopenia, as platelets rely on BCL-xL32.”

• cites [32] González-Gualda, E. et al. Galacto-conjugation of navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. Aging Cell 19, e13142 (2020). sourceNot checked yet

  A check is scheduled.

• cites [33] Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149–1159 (2010). sourceNot checked yet

  A check is scheduled.

• cites [34] Klener, P. et al. BH3 mimetics in hematologic malignancies. Int. J. Mol. Sci. 22, 10157 (2021). sourceNot checked yet

  A check is scheduled.

Senescent macrophages can induce ferroptosis in skeletal muscle during osteoarthritis progression.

“emerging evidence showing that senescent macrophages can induce ferroptosis in skeletal muscle during osteoarthritis progression78”

• cites [78] Xiang, W. et al. Senescent macrophages induce ferroptosis in skeletal muscle and accelerate osteoarthritis-related muscle atrophy. Nat. Aging 5, 1295–1316 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

DT2216-treated mice showed rapid platelet rebound following drug withdrawal.

“DT2216-treated mice showed rapid platelet rebound following drug withdrawal89”

• cites [89] He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020). sourceNot checked yet

The lack of reliable non-invasive biomarkers hampers patient stratification, therapeutic response monitoring, and dosing optimization, restricting clinical translation and personalization of senolytic interventions.

“This limitation hampers the ability to stratify patients, monitor therapeutic responses, and optimize dosing regimens, restricting the clinical translation and personalization of senolytic interventions:”

The gut-liver axis represents a promising target for improving both the efficacy and safety of senolytic interventions.

“In particular, the gut–liver axis represents a promising target for improving both the efficacy and safety of senolytic interventions.”

These next-generation strategies may overcome some limitations of early senolytics, which were frequently hampered by off-target toxicities and incomplete efficacy arising from the molecular heterogeneity of senescent cells.

“Collectively, these strategies may overcome some limitations of early senolytics, which were frequently hampered by off-target toxicities and incomplete efficacy arising from the molecular heterogeneity of SnCs2.”

• cites [2] Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813–827 (2019). sourceNot checked yet

An early-phase pilot study in idiopathic pulmonary fibrosis suggested modest functional trends with D+Q.

“An early-phase pilot study in IPF suggested modest functional trends36”

• cites [36] Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554–563 (2019). sourceNot checked yet

Navitoclax functions as a potent inhibitor of BCL-xL, BCL-2, and BCL-w.

“Navitoclax functions as a potent inhibitor of BCL-xL, BCL-2, and BCL-w.”

A novel galactomannan formulation from fenugreek seeds enhanced bioavailability up to 27-fold in a human study.

“A novel galactomannan formulation from fenugreek seeds enhanced bioavailability up to 27-fold in a human study43”

• cites [43] Krishnakumar, I. M. et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J. Nutr. Sci. 11, e74 (2022). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Immune-based senolysis applies immuno-oncology principles to counter immune evasion of senescent cells.

“the mechanisms underlying this immune escape closely mirror those utilized by tumor cells, offering valuable insights and a conceptual framework for the development of immune-based senotherapeutic strategies57,58.”

• cites [57] You, L. & Wu, Q. Cellular senescence in tumor immune escape: mechanisms, implications, and therapeutic potential. Crit. Rev. Oncol. Hematol. 208, 104628 (2025). sourceNot checked — no full text of the source
• cites [58] Song, P., An, J. & Zou, M. H. Immune clearance of senescent cells to combat ageing and chronic diseases. Cells 9, https://doi.org/10.3390/cells9030671 (2020). sourceNot checked yet

Inter-individual variability in gut microbiome composition poses a substantial challenge to translating microbiome-based senotherapeutic strategies into clinical practice.

“Translating these insights into clinical practice is challenging due to substantial inter-individual variability in gut microbiome composition.”

Butyrate functions as a histone deacetylase inhibitor, epigenetically regulating gene expression in the intestinal epithelium and liver.

“Butyrate functions as a potent histone deacetylase (HDAC) inhibitor, capable of epigenetically regulating gene expression in the intestinal epithelium and liver, thereby modulating systemic metabolic homeostasis99.”

• cites [99] Jing, M. & Jiang, Y. Microbiome-mediated crosstalk between T2DM and MASLD: a translational review focused on function. Front. Endocrinol. 16, 1677175 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Age-related shifts in gut microbiota modulate cellular senescence through intertwined metabolic and immune pathways.

“Recent studies have also mapped age-related shifts in gut microbiota, revealing functional changes that modulate cellular senescence through intertwined metabolic and immune pathways107,108.”

• cites [107] Yang, H. et al. Gut microbial-derived phenylacetylglutamine accelerates host cellular senescence. Nat. Aging 5, 401–418 (2025). sourceNot checked — no full text of the source
• cites [108] Wilmanski, T. et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat. Metab. 3, 274–286 (2021). sourceNot checked yet

Conjugated bile acids activate the farnesoid X receptor, suppressing hepatic stellate cell activation and fibrogenic signaling, thereby ameliorating liver fibrosis.

“Additional microbial metabolites, such as conjugated bile acids, can activate the farnesoid X receptor, suppressing hepatic stellate cell activation and fibrogenic signaling, thereby ameliorating liver fibrosis105,106.”

• cites [105] Fuchs, C. D. & Trauner, M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat. Rev. Gastroenterol. Hepatol. 19, 432–450 (2022). sourceNot checked — no full text of the source
• cites [106] Jang, D. H. et al. The connection between aging, cellular senescence and gut microbiome alterations: a comprehensive review. Aging Cell 23, e14315 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Multi-checkpoint blockade may offer a potent strategy to restore effective immune surveillance and clearance of senescent cells.

“These findings suggest that multi-checkpoint blockade may offer a potent strategy to restore effective immune surveillance and clearance of SnCs, though risks of immunopathology must be carefully managed.”

Comparative studies showed fisetin has greater potency than quercetin in some models.

“Comparative studies showed greater potency than quercetin in some models40,41.”

• cites [40] Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018). sourceNot checked yet
• cites [41] Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 9, 955–963 (2017). sourceNot checked yet

A Phase 2 trial in postmenopausal women showed limited biomarker changes with subtle or no significant clinical improvements in bone mass with D+Q.

“a Phase 2 trial in postmenopausal women showed limited biomarker changes with subtle or no significant clinical improvements in bone mass37.”

• cites [37] Farr, J. N. et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat. Med. 30, 2605–2612 (2024). sourceNot checked yet

GLS1 inhibitors such as BPTES or CB-839 selectively induce lethal acidification in a broad spectrum of senescent cells.

“GLS1 inhibitors such as BPTES or CB-839 have been shown to selectively induce lethal acidification in a broad spectrum of SnCs72,73”

• cites [72] Kim, J. et al. Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells. Cell Death Dis. 15, 902 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [73] Johmura, Y. et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science 371, 265–270 (2021). sourceNot checked — no full text of the source

The mechanisms underlying senescent cell immune escape closely mirror those utilized by tumor cells.

“the mechanisms underlying this immune escape closely mirror those utilized by tumor cells, offering valuable insights and a conceptual framework for the development of immune-based senotherapeutic strategies57,58.”

• cites [57] You, L. & Wu, Q. Cellular senescence in tumor immune escape: mechanisms, implications, and therapeutic potential. Crit. Rev. Oncol. Hematol. 208, 104628 (2025). sourceNot checked — no full text of the source
• cites [58] Song, P., An, J. & Zou, M. H. Immune clearance of senescent cells to combat ageing and chronic diseases. Cells 9, https://doi.org/10.3390/cells9030671 (2020). sourceNot checked yet

To maintain survival, senescent cells upregulate glutaminase 1 (GLS1), which converts glutamine into glutamate and ammonia, helping neutralize excess acidity.

“To maintain survival, they upregulate glutaminase 1 (GLS1), which converts glutamine into glutamate and ammonia, helping neutralize excess acidity.”

Senescent cells exhibit a distinctive epigenetic landscape.

“SnCs exhibit a distinctive epigenetic landscape, and the cfDNA they release may carry senescence-specific signatures115.”

• cites [115] Teo, Y. V. et al. Cell-free DNA as a biomarker of aging. Aging Cell 18, e12890 (2019). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

VHL E3 ligase is widely expressed in many tissues but minimally present in platelets.

“recruiting the VHL E3 ligase, which is widely expressed in many tissues but minimally present in platelets85.”

• cites [85] Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611–617 (2015). sourceNot checked yet

Interventions such as NAD+ supplementation and costimulatory domain optimization have been proposed to enhance T-cell durability and prevent dysfunction.

“Interventions such as NAD⁺ supplementation and costimulatory domain optimization have been proposed to enhance T-cell durability and prevent dysfunction70,71.”

• cites [70] Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [71] Fan, G., Wang, Y. & Wang, R. Recharging aged-CAR with NAD+ to boost immunotherapy. Trends Cancer 11, 711–712 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics face resistance mechanisms such as MCL-1 upregulation.

“resistance mechanisms such as MCL-1 upregulation, and negative outcomes in some models21”

• Also stated in: § The drive for precision · plain

  “the capacity of SnCs to evade elimination by upregulating alternative survival pathways (such as MCL-1)54,55”

• cites [21] McHugh, D., Durán, I. & Gil, J. Senescence as a therapeutic target in cancer and age-related diseases. Nat. Rev. Drug Discov. 24, 57–71 (2025). sourceNot checked — no full text of the source
• cites [54] Tantawy, S. I. et al. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front. Oncol. 13, 1226289 (2023). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [55] Troiani, M. et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat. Commun. 14, 4386 (2023). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Preclinical data suggest that stable microbiome alterations, typically achievable within 2-4 weeks of dietary intervention, are required to produce consistent effects.

“Preclinical data suggest that stable microbiome alterations, typically achievable within 2–4 weeks of dietary intervention, are required to produce consistent effects109.”

• cites [109] Boehme, M. et al. Microbiota from young mice counteracts selective age-associated behavioral deficits. Nat. Aging 1, 666–676 (2021). sourceNot checked — no full text of the source

Dual-targeting PROTACs capable of degrading both BCL-xL and BCL-2 demonstrate high efficacy in models of therapy-induced senescence.

“dual-targeting PROTACs capable of degrading both BCL-xL and BCL-2 have been developed, demonstrating high efficacy in models of therapy-induced senescence90,91.”

• cites [90] Khan, S. et al. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer. Cells 13, 528 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [91] Chang, L. C. et al. A first-in-class dual degrader of Bcl-2/Bcl-xL reverses HIV latency and minimizes ex vivo reservoirs from patients. Int. J. Mol. Sci. 26, 2772 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Senescent cells often exhibit lysosomal membrane damage, resulting in reduced intracellular pH (cytoplasmic acidification).

“SnCs often exhibit lysosomal membrane damage, resulting in reduced intracellular pH (cytoplasmic acidification).”

In oncology trials, 44-50% of patients experienced grade 3 or 4 thrombocytopenia.

“In oncology trials, 44–50% of patients experienced grade 3 or 4 thrombocytopenia33,34.”

• cites [33] Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149–1159 (2010). sourceNot checked yet
• cites [34] Klener, P. et al. BH3 mimetics in hematologic malignancies. Int. J. Mol. Sci. 22, 10157 (2021). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Additional targets under investigation for CAR-T-based senolytic therapies include NKG2D ligands and DPP4.

“Additional targets under investigation include NKG2D ligands and DPP4, expanding the potential repertoire for CAR-T–based senolytic therapies66.”

• cites [66] Huang, Y. & Liu, T. Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases. Signal Transduct. Target. Ther. 5, 155 (2020). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics provided critical proof-of-concept for the therapeutic potential of senescent cell clearance.

“First-generation senolytics provided critical proof-of-concept for the therapeutic potential of SnC clearance52.”

• cites [52] Carpenter, V. J., Saleh, T. & Gewirtz, D. A. Senolytics for cancer therapy: is all that glitters really gold?. Cancers 13, 723 (2021). sourceNot checked yet

Chloroquine has demonstrated senolytic activity in therapy-induced senescent glioblastoma cells by blocking autophagosome-lysosome fusion and reducing senescence markers.

“chloroquine has demonstrated senolytic activity in therapy-induced senescent glioblastoma cells by blocking autophagosome-lysosome fusion and reducing senescence markers50”

• cites [50] Beltzig, L., Christmann, M. & Kaina, B. Abrogation of cellular senescence induced by temozolomide in glioblastoma cells: search for senolytics. Cells 11, 2588–2588 (2022). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics target senescence-associated anti-apoptotic pathways (SCAPs).

“These first-generation senolytics target SnC anti-apoptotic pathways (SCAPs), which enable resistance to apoptosis despite SASP-induced stress8.”

• cites [8] Zhu, Y. et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging cell 14, 644–658 (2015). sourceNot checked yet

This strategy has been successfully applied to degrade intracellular targets like BRD4 in hepatic stellate cells, reversing hepatic fibrosis in murine models.

“This strategy has been successfully applied to degrade intracellular targets like BRD4 in hepatic stellate cells, reversing hepatic fibrosis in murine models93”

• cites [93] Yuan, S. et al. Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models. Theranostics 15, 7270–7290 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics navitoclax and the dasatinib-quercetin (D + Q) combination provided proof-of-concept that selective removal of senescent cells can alleviate certain fibrotic, metabolic, and cardiovascular pathologies in preclinical studies.

“Early “first-generation” senolytics, including navitoclax (ABT-263) and the dasatinib–quercetin (D + Q) combination, provided proof-of-concept that selective removal of SnCs can alleviate certain fibrotic, metabolic, and cardiovascular pathologies in preclinical studies.”

• Also stated in: § The drive for precision · plain

  “First-generation senolytics provided critical proof-of-concept for the therapeutic potential of SnC clearance52.”

• cites [52] Carpenter, V. J., Saleh, T. & Gewirtz, D. A. Senolytics for cancer therapy: is all that glitters really gold?. Cancers 13, 723 (2021). sourceNot checked yet

Next-generation senolytics may represent advances over first-generation agents, potentially offering enhanced selectivity, efficacy, and safety in selected models.

“Next-generation senolytics may represent advances over first-generation agents, potentially offering enhanced selectivity, efficacy, and safety in selected models (Table 2).”

A major challenge in senotherapy is the absence of reliable, non-invasive biomarkers for quantifying senescent cell burden in vivo.

“A major challenge in senotherapy is the absence of reliable, non-invasive biomarkers for quantifying SnC burden in vivo.”

Senescent cells can develop resistance to ferroptosis via ferritin-mediated iron sequestration or lysosomal dysfunction impairing cystine transport.

“Although SnCs can develop resistance mechanisms, such as ferritin-mediated iron sequestration or lysosomal dysfunction impairing cystine transport75”

• cites [75] Loo, T. M. et al. Senescence-associated lysosomal dysfunction impairs cystine deprivation-induced lipid peroxidation and ferroptosis. Nat. Commun. 16, 6617 (2025). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

The gut microbiome is a key regulator of host metabolism and immune function.

“The gut microbiome has emerged as a key regulator of host metabolism and immune function, carrying significant implications for senotherapeutic strategies97.”

• cites [97] Boyajian, J. L. et al. Microbiome and human aging: probiotic and prebiotic potentials in longevity, skin health and cellular senescence. Nutrients 13, 4550 (2021). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Clinical translation of first-generation senolytics is hampered by limited specificity, resulting in on-target, off-tissue toxicities.

“their clinical translation is hampered by limited specificity, resulting in on-target, off-tissue toxicities53.”

• cites [53] Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340–355 (2022). sourceNot checked — no full text of the source

Genome-wide CRISPR screens and transcriptomic profiling have identified uPAR as a leading candidate for senescence-specific targeting.

“Genome-wide CRISPR screens and transcriptomic profiling have identified several promising SnC-specific targets, with urokinase-type plasminogen activator receptor (uPAR) emerging as a leading candidate63,64”

• cites [63] Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127–132 (2020). sourceNot checked yet
• cites [64] Deng, Y. et al. Targeting senescent cells with NKG2D-CAR T cells. Cell Death Discov. 10, 217 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

First-generation senolytics exhibit variable therapeutic efficacy.

“these agents exhibited notable drawbacks, such as dose-dependent thrombocytopenia, variable therapeutic efficacy, and the emergence of resistance mechanisms.”

• Also stated in: § Representative agents in greater detail · plain

  “the efficacy of D + Q and other senolytics has shown variability across models and contexts, with inconsistent effects on senescence markers and limited evidence of lifespan extension in more rigorous or genetically diverse preclinical settings38”

• cites [38] Lelarge, V. et al. Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients’ treatment. NPJ Aging 10, 12 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

SASP factors such as IL-6 lack specificity as biomarkers.

“While measurement of SASP factors, such as IL-6, is common, these markers lack specificity117.”

• cites [117] Mansfield, L. et al. Emerging insights in senescence: pathways from preclinical models to therapeutic innovations. NPJ Aging 10, 53 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

According to the antagonistic pleiotropy theory, senescence is a conserved mechanism that confers early-life benefits, notably tumor suppression and wound healing, while contributing to age-related decline later in life.

“According to the antagonistic pleiotropy theory, senescence is a conserved mechanism that confers early-life benefits, notably tumor suppression and wound healing, while contributing to age-related decline later in life132.”

• cites [132] Inci, N. et al. Translation of cellular senescence to novel therapeutics: insights from alternative tools and models. Front. Aging 3, 828058 (2022). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

These immune-related risks may be amplified in older patients due to underlying immune dysregulation associated with "inflammaging."

“These risks may be amplified in older patients due to underlying immune dysregulation associated with “inflammaging.””

• cites [118] Wang, X. et al. Rejuvenation strategy for inducing and enhancing autoimmune response to eliminate senescent cells. Aging Dis. 16, 2273–2292 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

• cites [119] Khan, S. et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120, 63–68 (2019). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

Systematically eliminating senescence, especially with persistent "living drugs" like CAR-T cells, may carry unforeseen long-term risks.

“Systematically eliminating senescence, especially with persistent “living drugs” like CAR-T cells, may carry unforeseen long-term risks.”

Hormonal status may modulate senolytic efficacy.

“indicating that hormonal status may modulate senolytic efficacy121.”

• cites [121] Rani, A. et al. Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging. Front. Aging Neurosci. 16, 1384554 (2024). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

The cfDNA released by senescent cells may carry senescence-specific signatures.

“SnCs exhibit a distinctive epigenetic landscape, and the cfDNA they release may carry senescence-specific signatures115.”

• cites [115] Teo, Y. V. et al. Cell-free DNA as a biomarker of aging. Aging Cell 18, e12890 (2019). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.

The high production costs of CAR-T cells and PROTACs may limit patient accessibility.

“The high production costs of CAR-T cells and PROTACs, reflecting complex manufacturing and purification processes, may limit patient accessibility123.”

• cites [123] Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518–536 (2020). sourceNot checked yet

The targeting aging with metformin trial seeks to establish a regulatory precedent for aging as a treatable indication by employing a composite endpoint encompassing multiple age-related diseases.

“A notable initiative addressing this gap is the targeting aging with metformin trial, which seeks to establish a regulatory precedent for aging as a treatable indication by employing a composite endpoint encompassing multiple age-related diseases124.”

• cites [124] Kulkarni, A. S., Gubbi, S. & Barzilai, N. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 32, 15–30 (2020). sourceNot checked yet

• AssumptionRests on an assumption: Regulatory bodies such as the FDA currently approve therapies for specific diseases rather than for “aging” itself.

Individual variability in response to senolytic therapies can arise from sex differences, microbiome composition, and pharmacogenomic factors.

“Individual variability in response to senolytic therapies can arise from sex differences (such as hormonal regulation of drug transporters and immune targets), microbiome composition, and pharmacogenomic factors120.”

• cites [120] Justice, J. N. et al. Development of clinical trials to extend healthy lifespan. Cardiovasc. Endocrinol. Metab. 7, 80–83 (2018). sourceNot checked yet

Next-generation senolytics face substantial regulatory and economic hurdles.

“Next-generation senolytics face substantial regulatory and economic hurdles.”

• AssumptionRests on an assumption: Regulatory bodies such as the FDA currently approve therapies for specific diseases rather than for “aging” itself.

Machine learning pipelines trained on extensive chemical compound datasets have identified novel small-molecule senolytics, such as Ginkgetin, Periplocin, and Oleandrin.

“Machine learning pipelines, trained on extensive chemical compound datasets, have already identified novel small-molecule senolytics, such as Ginkgetin, Periplocin, and Oleandrin, and predicted synergistic drug combinations, substantially reducing the time and cost of discovery127,128.”

• cites [127] Wong, F. et al. Discovering small-molecule senolytics with deep neural networks. Nat. Aging 3, 734–750 (2023). sourceNot checked — no full text of the source
• cites [128] Smer-Barreto, V. et al. Discovery of senolytics using machine learning. Nat. Commun. 14, 3445 (2023). sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.